Key facts
- This page summarizes Marijn E. Dekkers's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2024, 16:22.
Marijn E. Dekkers - 12 Jun 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)
- Reporting relationship
- Director
- Issuer ticker
- DNA
- Reported as of
- 12 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 16:22:28 UTC
- Prior SEC filing
- 07 Jun 2024
- Next SEC filing
- 05 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karen Tepichin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Marijn E. Dekkers filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 07 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNA
transaction
Class A Common Stock
Options Exercise
- Transaction value
- Shares
- +105,263
- Change %
- +37%
- Price
- Shares after
- 386,480
- Date
- 12 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
DNA
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,515,364
- Date
- 12 Jun 2024
- Ownership
- By Novalis LifeSciences Investments I, L.P.
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -105,263
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Jun 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 105,263
- Exercise price
- $0.000000
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Marijn E. Dekkers is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Footnote F2
Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
Footnote F3
The Reporting Person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
Footnote F4
In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.